Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

5 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

UBI, UNIVERSAL BIOSENSORS, INC.
nipper
post Posted: Sep 14 2021, 03:19 PM
  Quote Post


Posts: 10,050
Thanks: 2814


In Reply To: nipper's post @ Apr 13 2021, 12:59 PM

some specifics.
QUOTE
UBI has entered into an agreement with the Peter MacCallum Cancer Centre (Peter Mac) to supply cancer patient samples which will be used to develop and validate the performance of UBI's handheld point-of-care cancer biosensor for Tn Antigen (Tn).

This agreement provides UBI with access to plasma samples collected from patients with colorectal, breast and prostate cancer as part of a Peter Mac research initiative. Trial results will be used to confirm the presence of Tn in multiple cancer types and determine the clinically relevant range of Tn concentrations.

The trial is scheduled to commence during October and results should be available during Q1 2022.

lead times of regulatory pathway means it will be 2024 before it is a reality




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Apr 13 2021, 12:59 PM
  Quote Post


Posts: 10,050
Thanks: 2814


In Reply To: dr_dazmo's post @ Dec 9 2014, 10:55 AM

looking at UBI, maybe 2014 was the beginning of the long sleep. There was one good year 2018 when Earnings were +ve but since then it seems to be eating capital again. .... But it may be waking up .... 20c to 60c in 12 months.
QUOTE
UBI is a biosensor company and world leader in electrochemical cell technology with a long history of innovation and establishing global partnerships.

UBI's biosensor technology platform has been used to deliver more than 10 billion diagnostic tests to patients worldwide generating billions of dollars in sales


The biosensor market is estimated at AUD $40 billion. Point of Care diagnostics and screening are among the key reasons for the overall increase in global demand for biosensors.

Advancements in biosensor technology and its applications include increased detection limits and miniaturization.
Recently launched Sentia, which delivers medical grade biosensor technology to the wine industry. Products include Free SO2 testing (launch Feb 21), Glucose, Fructose and Malic Acid (launch during 2021) and Acetic and Total Acid (launch during 2022). Sentia delivers testing specificity and sensitivity, significant cost savings and productivity gains to the wine industry.

Looking for a Veterinary application, to develop and commercialise a Vet blood glucose strip and meter.

They have Xprecia Stride Coagulation Analyser is a handheld device that reports PT/INR levels at the point of care with laboratory accuracy, for patients taking Warfarin. Xprecia Stride has been sold by Siemens Healthineers since December 2014. In 2019, UBI bought back the global distribution rights. There is an installed base of over 3,500 units throughout the world and Xprecia Stride is sold in 36 countries. UBI's next generation PT-INR Coagulation Analyser is currently in development.
UBI is currently performing due diligence on a number of separate technology opportunities. Each technology has the capability to increase the detection limits for our existing platform technology from Micromolar to Picomolar or better.

QUOTE
and today's news ; DIFM (Deakin U) and Swinburne have been working on the next generation of electrochemical biosensors and the Tn Antigen cancer biomarker for more than 5 years. Using UBI’s platform technology we plan to deliver a cancer biosensor capable of identifying, staging and monitoring cancer from a finger prick of blood, using a portable hand held device. The knowledge and resources of DIFM and Swinburne will help deliver this as well as fast track the development of other biosensors we are working on.





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
dr_dazmo
post Posted: Dec 9 2014, 10:55 AM
  Quote Post


Posts: 2,199
Thanks: 647


Hi All,
This thread seems a bit of a sleepy backwater, but UBI looks interesting (to me).
Market Cap is about $25M, they had cash of approx $20m at 30/9/14, and seems to be gaining some traction with their products.

Might be worth a look.

Cheers
Dr_Dazmo





--------------------
Always remember the Golden Rule - Those with the Gold make the Rules!
 
floyd
post Posted: Sep 27 2011, 11:27 AM
  Quote Post


Posts: 1,215
Thanks: 103


updated veritas securities report on the ubi website, its from the 22nd of sept

http://www.universalbiosensors.com/site/De...1Report.pdf.pdf




--------------------


 
floyd
post Posted: Sep 14 2011, 02:48 PM
  Quote Post


Posts: 1,215
Thanks: 103


In Reply To: oracle's post @ Sep 14 2011, 01:38 PM

if/when lifescan launch this new meter in the states hopefully it will a big launch to include europe as well... all would bode well for ubi



--------------------


 
oracle
post Posted: Sep 14 2011, 01:38 PM
  Quote Post


Posts: 787
Thanks: 21


In Reply To: oracle's post @ Sep 9 2011, 11:26 AM

FDA approval for the new meter. Now if Lifescan could get going on a US launch we might be able to get volumes up and get manufacturing into the black.



--------------------
oracle
 


oracle
post Posted: Sep 9 2011, 11:26 AM
  Quote Post


Posts: 787
Thanks: 21


In Reply To: floyd's post @ Sep 9 2011, 09:29 AM

...and the prospect of a further deal in the patient self testing market. "in discussions"
Good stuff...



--------------------
oracle
 
floyd
post Posted: Sep 9 2011, 09:29 AM
  Quote Post


Posts: 1,215
Thanks: 103


annoucement out

Enters into Strategic Partnership with Siemens Healthcare

getting into bed with another big company, 3 mill up front with 6 more milestone based payments along with revenue from each strip manufactured.... way to go ubi biggrin.gif




--------------------


 
oracle
post Posted: Sep 8 2011, 11:09 AM
  Quote Post


Posts: 787
Thanks: 21


In Reply To: floyd's post @ Sep 8 2011, 10:54 AM

Yes might explain Lifescans rather listless performance so far.
Thanks for that.



--------------------
oracle
 
floyd
post Posted: Sep 8 2011, 10:54 AM
  Quote Post


Posts: 1,215
Thanks: 103


found this interesting from the analysts report...

While the OneTouch Verio meter received regulatory approval in the USA in February 2011, we believe LifeScan is waiting for the imminent approval of an upgraded meter before launching in the US, probably during 2H CY2011. The promotion will be based on an advantage over competing products, being accurate, precise, and cost effective. We also expect a corresponding increase in promotion in Europe around this meter.

so while we've been awaiting the launch of the verio meters, theres actually an upgraded model coming out... first time id heard of this.




--------------------


 
 


5 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING